Method for Treating Diabetic Ulcers with Vectors Encoding VEGF (Patent)

United States Patent 7,919,478
Inventor: Harold Brem
April 5, 2011

This patent covers a sustained-release method developed by Dr. Harold Brem and his research colleagues to deliver a therapeutic dose of the angiogenic molecule Vascular Endothelial Growth Factor (VEGF) in a way that accelerates the rate of healing in experimental diabetic ulcers. Dysfunctional angiogenesis (blood vessel growth) has been suggested as a common origin for impaired wound healing, retinopathy, nephropathy, and neuropathy in patients. VEGF administered locally into diabetic wounds is the safest and most effective method to stimulate angiogenesis and to facilitate healing of these wounds. Dr. Brem and his research team have shown that in addition to its pro-angiogenic effects, VEGF delivered by adenoviral vector (ADV) promotes migration of keratinocytes and fibroblasts, and increases collagen deposition and granulation tissue formation in diabetic wounds. Sustained administration of ADV-VEGF stimulates and accelerates the healing process as evidenced by a reduced time to complete healing (defined by 100% epithelialization and no drainage), with minimal to no toxicity.

In addition to ADV, polymeric matrices can also be used as sustained release device for VEGF delivery. Important features of all these discoveries are that these methods enable the VEGF to be released into the ulcer in a sufficient quantity to be effective over a period of 2 to 6 weeks, or to closure of the wound. In the future, local delivery and sustained, controlled release of VEGF may decrease amputations in patients with diabetic foot ulcers and accelerate closure of venous ulcers and pressure ulcers.

Click on the following link to visit the U.S. Patent Office website and read the full description of this patent.

item8 item8